Tvardi Therapeutics, Inc. 8-K

What Happened

• Tvardi Therapeutics, Inc. filed a Form 8-K (Item 7.01) dated July 7, 2026 to disclose clinical updates for its investigational drug TTI-109. The company issued a press release titled "Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement" and posted an updated corporate presentation to discuss the results. The press release is attached as Exhibit 99.1 and the presentation as Exhibit 99.2 to the filing.

Key Details

• Filing date: July 7, 2026 (Form 8-K, Item 7.01 disclosure).
• Primary clinical messages: Phase 1 data reportedly confirm TTI-109’s prodrug design, show improved tolerability, and provide pharmacodynamic evidence of STAT3 target engagement.
• Materials made public: Press release (Exhibit 99.1) and updated corporate presentation (Exhibit 99.2).
• Regulation FD: Disclosure was made publicly under Regulation FD (Item 7.01).

Why It Matters

• For investors, the announcement signals clinical progress for TTI-109—validation of the prodrug design, better tolerability, and evidence of target engagement (STAT3) are important early-stage milestones that can de-risk development if supported by full data. The filing does not present detailed numerical trial results or financial information; it primarily makes the company’s press release and presentation publicly available. Investors should review the attached press release and presentation for specifics and await full data releases or company guidance for more complete evaluation.